Introduction

On April 9, 2026, Henlius' biosimilar rituximab, Hanlikang®, received approval from China's NMPA for two additional non-Hodgkin lymphoma indications, completing its coverage of all domestic indications for the reference product. As China's first biosimilar, its rigorous CMC, clinical, and quality standards present a credible alternative for global markets, particularly cost-sensitive public healthcare procurement programs requiring GMP and clinical equivalence. This development is significant for biopharmaceutical manufacturers, procurement agencies, and regulatory bodies.

Event Overview

On April 9, 2026, the NMPA approved Henlius' Hanlikang® for two new non-Hodgkin lymphoma indications, marking full therapeutic equivalence to the originator rituximab in China. The biosimilar has met stringent regulatory reviews in China and holds potential for EMA, FDA, and emerging market approvals, positioning it as a compliant procurement option.

Impact on Sub-Sectors

Biopharmaceutical Manufacturers

Biosimilar developers may face intensified competition in emerging markets, where Hanlikang®’s regulatory milestones could set precedents for local approval pathways. Manufacturers should reassess portfolio strategies for lymphoma therapies.

Procurement Agencies

Public health systems in cost-sensitive regions (e.g., Latin America, Middle East) gain a vetted alternative. Agencies should verify Hanlikang®’s WHO-prequalification status for tender eligibility.

Regulatory Consultants

Increased demand for bridging study designs between China and target markets is expected. Consultants should monitor NMPA-EMA/FDA alignment trends.

Key Considerations for Stakeholders

Monitor Regulatory Convergence

Track NMPA’s evolving biosimilar guidelines as potential benchmarks for emerging markets.

Evaluate Supply Chain Readiness

Importers should audit Henlius’ production scalability to ensure stable supply for large tenders.

Differentiate Procurement Criteria

Payers must distinguish between price-driven bids and clinically validated biosimilars in tender designs.

Industry Observation

This approval signals China’s growing capacity to produce globally competitive biosimilars. While not an immediate market disruptor, it establishes a reference model for emerging market manufacturers. The long-term impact hinges on sustained compliance with international GMP standards post-approval.

Conclusion

Hanlikang®’s expanded approval reinforces China’s role in biosimilar globalization but requires cautious adoption. Stakeholders should treat this as a case study in regulatory harmonization rather than an immediate procurement solution.

Sources

1. NMPA Approval Announcement (April 9, 2026)
2. Henlius Corporate Disclosure
*Ongoing: Monitoring WHO prequalification status for Hanlikang®